Tyrosine Kinase Inhibitors and Stem Cell Transplantation – Shaping The Treatment Landscape Of CML
Article Index
Tyrosine Kinase Inhibitors and Stem Cell Transplantation – Shaping The Treatment Landscape Of CML
CME Information
Presentations
 

 

bmtrp_0705_header 

radich

Tyrosine Kinase Inhibitors: Redefining Treatment
Algorithms for CML

Jerald P. Radich, MD
Professor of Medicine
University of Washington School of Medicine
Member, Clinical Research Division
Fred Hutchinson Cancer Research Center
Seattle, Washington

View Presentation  

 
giralt_sergio

 


Stem Cell Transplantation in Patients With CML: When Should It Be Used?
Sergio A. Giralt, MD

Associate Professor of Medicine
Clinical Medical Director
Department of Blood and Marrow Transplantation
University of Texas M.D. Anderson Cancer Center
Houston, Texas

View Presentation  

 
shah

 

New Options for Patients With Imatinib Resistance
Neil P. Shah, MD, PhD

Assistant Professor of Hematology/Oncology
Department of Medicine
University of California, San Francisco
School of Medicine
San Francisco, California

View Presentation  

 
bms_sml_cover

 

Question and Answer Session
Chairman and Faculty Panel
View Presentation  

 

 

pdf Download a PDF of the Program Post-Test and Activity Evaluation/Request for CME Credit Form